New York State Medicaid
NYRx Preferred Drug Program - 2023 Therapeutic Class Review
Preferred Drug Program Legislation

The New York State Medicaid Drug Utilization Review (DUR) Board intends to review the following therapeutic classes in 2023 as they pertain to the NYRx, the fee-for-service Preferred Drug Program (PDP). For the therapeutic classes below, new relevant clinical and/or financial information is known to exist. DUR Board meeting agendas for 2023 are posted to the Department of Health (DOH) website (DUR Program) thirty (30) days prior to the meeting date.

Therapeutic Category	Therapeutic Class	Previous Review Date
Cardiovascular	Angiotensin Receptor Blockers	4/15/2011
	Angiotensin Receptor Blocker Combinations	11/5/2020
	Triglyceride Lowering Agents	5/13/2021
Central Nervous System	Anticonvulsants - Other	7/15/2021
	Multiple Sclerosis Agents	7/15/2021
	Selective Serotonin Reuptake Inhibitors	4/27/2016
Dermatologic Agents	Psoriasis Agents - Topical	4/22/2015
Endocrine and Metabolic Agents	Dipeptidyl Peptidase 4 Inhibitors	4/26/2018
	Glucagon Agents	7/14/2022
	Glucagon-like Peptide 1 Agonists	5/12/2022
Gastrointestinal	Proton Pump Inhibitors	4/19/2012
Hematological Agents	Erythropoiesis Stimulating Agents	5/16/2019
Immunologic Agents	Immunomodulators - Systemic	7/14/2022
	Immunosuppressives - Oral	7/23/2020
Ophthalmics	Antihistamines – Ophthalmic	4/26/2018
Renal and Genitourinary	Urinary Tract Antispasmodics	4/22/2015
Respiratory	Anticholinergics / COPD Agents	5/12/2022
	Antihistamines - Second Generation	4/27/2016
	Beta 2 Adrenergic Agents – Inhaled Long Acting	4/27/2016

*The NYRx Preferred Drug List (PDL) may be viewed at NYRx PDL.

As of April 2023, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes, since previously reviewed, and the DOH proposes no changes to the NYRx PDL. If interested parties have new relevant clinical information, it can be submitted (to dur@health.ny.gov) as it becomes available. When submitting new relevant clinical information, please reference the DUR Board and PDP therapeutic class. DOH will consider new relevant clinical information provided when developing future DUR Board meeting agendas.

In determining and submitting new clinical information, the previous review dates for all therapeutic classes are available on prior meeting agendas which may be viewed at DUR Program. New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials. Comparative evidence is preferred, or placebo controlled when no head-to-head trials are available. Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of review and submission is discouraged.

Please continue to monitor the DOH website for DUR Board meeting schedules and agendas at DUR Program.